You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Single-cell RNA sequencing on adrenal gland samples with or without neuroblastoma helped track down key malignant subtypes and tumor features, providing prognostic clues.
Using proteomic, phosphoproteomic, and genomic data, researchers uncovered informative features in primary and metastatic samples from almost 150 CRC cases in China.
Tumor microenvironment cell transcriptomes pointed to four stromal cell clusters, including immune interacting support cells predicted to impact immunotherapy response.
The collaboration seeks to develop RNA-based signatures that could help oncologists predict disease progression and guide the use of precision therapies.
While a subset of metastatic castration-resistant tumors was marked by enhanced methylation, the analysis also pointed to recurrently hypomethylated regions.
Investigators are planning to further validate specific applications, such as prediction of lung and lymphoma cancer subtypes, in independent sample sets.
GNS Healthcare will apply its AI and simulation technology to data from the CoMMpass study in search of insights on disease progression and drug response.
Women with breast cancer from Peru, Mexico, or Colombia who had greater Indigenous American ancestry were more likely to have HER2-positive tumors.
Researchers identified 10 protein-based tumor subtypes across five cancer types, including subtypes representing immune cell features in the tumor microenvironment.
Analyzing patient exome sequence data, investigators identified germline variants with apparent ties to estrogen receptor-positive breast cancer recurrence.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.